| __timestamp | ADMA Biologics, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 2704597 |
| Thursday, January 1, 2015 | 7015946 | 15470000 |
| Friday, January 1, 2016 | 7688238 | 28037000 |
| Sunday, January 1, 2017 | 6229587 | 71615000 |
| Monday, January 1, 2018 | 3926120 | 99828000 |
| Tuesday, January 1, 2019 | 2343848 | 166023000 |
| Wednesday, January 1, 2020 | 5907013 | 201727000 |
| Friday, January 1, 2021 | 3646060 | 259039000 |
| Saturday, January 1, 2022 | 3613764 | 294781000 |
| Sunday, January 1, 2023 | 3300000 | 344077000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Iovance Biotherapeutics, Inc. has consistently outpaced ADMA Biologics, Inc. in R&D investment. From 2014 to 2023, Iovance's R&D expenses surged by over 12,000%, peaking at approximately $344 million in 2023. In contrast, ADMA's R&D spending saw a decline of about 65% during the same period, ending at around $3.3 million in 2023.
This stark difference highlights Iovance's aggressive pursuit of cutting-edge therapies, while ADMA appears to be more conservative in its innovation strategy. As the biotech industry continues to evolve, these spending patterns may influence each company's ability to bring new treatments to market and capture market share.
Research and Development: Comparing Key Metrics for Merck & Co., Inc. and Iovance Biotherapeutics, Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs ADMA Biologics, Inc.
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: Grifols, S.A. and ADMA Biologics, Inc.
TG Therapeutics, Inc. or Iovance Biotherapeutics, Inc.: Who Invests More in Innovation?
Research and Development Investment: ADMA Biologics, Inc. vs Xenon Pharmaceuticals Inc.
Research and Development Investment: ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Analyzing R&D Budgets: Perrigo Company plc vs Iovance Biotherapeutics, Inc.
R&D Insights: How Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds
R&D Insights: How Iovance Biotherapeutics, Inc. and Evotec SE Allocate Funds